F-MISO PET in borderline resectable pancreatic cancer
Research type
Research Study
Full title
The Correlation of Hypoxic Imaging, using PET Fluromisonidazole (F-MISO), with pathological specimens in patients undergoing NeoAdjuvant (chemo) radiotherapy for borderline resectable pancreatic cancer
IRAS ID
194525
Contact name
Derek Grose
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde Clinical Research and Development Central Office
Duration of Study in the UK
1 years, 6 months, 5 days
Research summary
Pancreatic cancer has one of the worst outlooks of any common cancer. Even in the relatively unusual situation of it being potentially operable the chance of cure is very small. There are two main reasons for this. Firstly pancreatic cancer spreads to other parts of the body frequently, secondly even when the cancer is removed there is a fairly high chance of microscopic regions of cancer being left behind
There is a lot of interest in giving treatment (chemotherapy and radiotherapy) before an operation to try to improve the chances of no cancer being left behind. At present we don’t know which patients are more likely to respond to these types of treatments.
A new type of scanner called a PET scan is able to both identify the cancer and potentially show areas which have a poor blood supply. Many studies have shown that high levels of such areas, referred to as hypoxic regions, reduce the chance of the cancer responding to the treatment.
We wish to determine whether this type of scan is able to demonstrate such areas and thus predict response to treatment.Each of the 10 patients would have 3 scans during the standard preoperative treatment regime.
REC name
West of Scotland REC 3
REC reference
16/WS/0113
Date of REC Opinion
29 Jun 2016
REC opinion
Favourable Opinion